Ms. Delphine Vandame | Link Prediction | Best Researcher Award
Biocodex | France
Delphine Vandame, PhD, is an accomplished Global Medical Affairs leader with a strong scientific foundation in neuropharmacology and more than 15 years of progressive experience across the pharmaceutical and biotechnology sectors. Driven by a deep passion for science, resilience, and adaptability within the evolving healthcare environment, she currently serves as Global Medical Affairs Head at Biocodex, where she directs worldwide medical strategy for Diacomit in rare pediatric epilepsy, oversees a team of seven Medical Advisors, accelerates digital transformation through AI-driven insight and analytics, and strengthens strategic capabilities across international affiliates. Prior to this, she held key leadership roles at UCB Pharma, including Ecosystem Lead-where she designed and executed immunology strategies for Cimzia and Bimzelx, created a new dermatology business unit, and led a multifunctional medical–commercial team recognized with the 2019 Best MSL Team in EU award-and Medical Manager, guiding EU and French medical strategy across rheumatology and dermatology indications. Earlier roles include Medical Affairs Project Manager at Boehringer Ingelheim, Senior Project Manager at WPP supporting top global pharma organizations, Business Developer at Universal Biotech, Project Manager at CNRS, and Researcher at INSERM and the University of Texas, during which she secured grant funding, contributed to R&D programs, and presented internationally. Dr. Vandame holds a PhD in Neuropharmacology from the Pharmaceutical University of Montpellier, dual Master’s degrees in Biochemistry and Chemistry, and executive leadership training from HEC Paris and Krauthammer; recognized for her work ethic, strategic drive, and leadership excellence, she continues to thrive in fast-paced, cross-functional environments where innovation, scientific rigor, and patient-centric impact intersect.
Profiles: Scopus | Orcid
Featured Publications
"Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis", Delphine Vandame, Epilepsia, 2024.